This report was first published by Endpoints News. To see the original version, click here
FDA Commissioner Marty Makary offered a very skeptical take on the trustworthiness told a supply chain resiliency meeting at the National Academies of Sciences, Engineering, and Medicine in late October.
If your Phase One trials in the United States, maybe you should pay a higher user fee.
您已閱讀41%（379字），剩余59%（550字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。